#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-6	GABRA2	_
1-2	7-22	rs279858-linked	_
1-3	23-31	variants	_
1-4	32-35	are	_
1-5	36-46	associated	_
1-6	47-51	with	_
1-7	52-61	disrupted	_
1-8	62-72	structural	_
1-9	73-83	connectome	_
1-10	84-86	of	_
1-11	87-93	reward	_
1-12	94-102	circuits	_
1-13	103-105	in	_
1-14	106-112	heroin	_
1-15	113-120	abusers	_
1-16	121-124	The	_
1-17	125-131	reward	_
1-18	132-138	system	_
1-19	139-144	plays	_
1-20	145-146	a	_
1-21	147-152	vital	_
1-22	153-157	role	_
1-23	158-160	in	_
1-24	161-165	drug	_
1-25	166-175	addiction	_
1-26	176-177	.	_

2-1	178-181	The	_
2-2	182-189	purpose	_
2-3	190-192	of	_
2-4	193-197	this	_
2-5	198-203	study	_
2-6	204-206	is	_
2-7	207-209	to	_
2-8	210-221	investigate	_
2-9	222-225	the	_
2-10	226-236	structural	_
2-11	237-249	connectivity	_
2-12	250-265	characteristics	_
2-13	266-269	and	_
2-14	270-285	driving-control	_
2-15	286-296	subnetwork	_
2-16	297-305	patterns	_
2-17	306-308	of	_
2-18	309-315	reward	_
2-19	316-324	circuits	_
2-20	325-327	in	_
2-21	328-334	heroin	_
2-22	335-342	abusers	_
2-23	343-346	and	_
2-24	347-353	assess	_
2-25	354-357	the	_
2-26	358-365	genetic	_
2-27	366-376	modulation	_
2-28	377-379	on	_
2-29	380-383	the	_
2-30	384-390	reward	_
2-31	391-398	network	_
2-32	399-400	.	_

3-1	401-403	We	_
3-2	404-409	first	_
3-3	410-417	defined	_
3-4	418-421	the	_
3-5	422-428	reward	_
3-6	429-436	network	_
3-7	437-442	based	_
3-8	443-445	on	_
3-9	446-456	systematic	_
3-10	457-467	literature	_
3-11	468-474	review	_
3-12	475-476	,	_
3-13	477-480	and	_
3-14	481-486	built	_
3-15	487-490	the	_
3-16	491-497	reward	_
3-17	498-505	network	_
3-18	506-511	based	_
3-19	512-514	on	_
3-20	515-524	diffusion	_
3-21	525-531	tensor	_
3-22	532-539	imaging	_
3-23	540-544	data	_
3-24	545-547	of	_
3-25	548-550	78	_
3-26	551-557	heroin	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse
3-27	558-565	abusers	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse
3-28	566-567	(	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse
3-29	568-571	HAs	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse
3-30	572-573	)	_
3-31	574-577	and	_
3-32	578-580	79	_
3-33	581-588	healthy	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
3-34	589-597	controls	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
3-35	598-599	(	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
3-36	600-603	HCs	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
3-37	604-605	)	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
3-38	606-611	using	_
3-39	612-622	structural	_
3-40	623-635	connectomics	_
3-41	636-637	.	_

4-1	638-642	Then	_
4-2	643-645	we	_
4-3	646-654	assessed	_
4-4	655-662	genetic	_
4-5	663-670	factors	_
4-6	671-675	that	_
4-7	676-681	might	_
4-8	682-690	modulate	_
4-9	691-698	changes	_
4-10	699-701	in	_
4-11	702-705	the	_
4-12	706-712	reward	_
4-13	713-720	network	_
4-14	721-723	by	_
4-15	724-734	performing	_
4-16	735-750	imaging-genetic	_
4-17	751-760	screening	_
4-18	761-764	for	_
4-19	765-767	22	_
4-20	768-785	addiction-related	_
4-21	786-799	polymorphisms	_
4-22	800-801	.	_

5-1	802-805	The	_
5-2	806-813	genetic	_
5-3	814-825	association	_
5-4	826-829	was	_
5-5	830-839	validated	_
5-6	840-842	by	_
5-7	843-853	performing	_
5-8	854-861	genetic	_
5-9	862-874	associations	_
5-10	875-876	(	_
5-11	877-881	1032	_
5-12	882-885	HAs	_
5-13	886-889	and	_
5-14	890-894	2863	_
5-15	895-898	HCs	_
5-16	899-900	)	_
5-17	901-904	and	_
5-18	905-921	expanded-variant	_
5-19	922-930	analysis	_
5-20	931-932	.	_

6-1	933-940	Finally	_
6-2	941-942	,	_
6-3	943-945	we	_
6-4	946-955	estimated	_
6-5	956-959	the	_
6-6	960-971	association	_
6-7	972-979	between	_
6-8	980-985	these	_
6-9	986-993	genetic	_
6-10	994-1004	variations	_
6-11	1005-1006	,	_
6-12	1007-1013	reward	_
6-13	1014-1021	network	_
6-14	1022-1023	,	_
6-15	1024-1027	and	_
6-16	1028-1036	clinical	_
6-17	1037-1048	performance	_
6-18	1049-1050	.	_

7-1	1051-1053	We	_
7-2	1054-1059	found	_
7-3	1060-1064	that	_
7-4	1065-1068	HAs	_
7-5	1069-1072	had	_
7-6	1073-1083	widespread	_
7-7	1084-1096	deficiencies	_
7-8	1097-1099	in	_
7-9	1100-1103	the	_
7-10	1104-1114	structural	_
7-11	1115-1127	connectivity	_
7-12	1128-1130	of	_
7-13	1131-1134	the	_
7-14	1135-1141	reward	_
7-15	1142-1149	circuit	_
7-16	1150-1151	(	_
7-17	1152-1158	center	_
7-18	1159-1161	in	_
7-19	1162-1172	VTA-linked	_
7-20	1173-1184	connections	_
7-21	1185-1186	)	_
7-22	1187-1188	,	_
7-23	1189-1194	which	_
7-24	1195-1205	correlated	_
7-25	1206-1210	with	_
7-26	1211-1220	cognition	_
7-27	1221-1231	deficiency	_
7-28	1232-1233	.	_

8-1	1234-1237	The	_
8-2	1238-1249	disruptions	_
8-3	1250-1263	synchronously	_
8-4	1264-1268	were	_
8-5	1269-1274	shown	_
8-6	1275-1277	on	_
8-7	1278-1281	the	_
8-8	1282-1288	reward	_
8-9	1289-1296	driving	_
8-10	1297-1303	system	_
8-11	1304-1307	and	_
8-12	1308-1314	reward	_
8-13	1315-1322	control	_
8-14	1323-1329	system	_
8-15	1330-1331	.	_

9-1	1332-1338	GABRA2	_
9-2	1339-1354	rs279858-linked	_
9-3	1355-1363	variants	_
9-4	1364-1369	might	_
9-5	1370-1372	be	_
9-6	1373-1374	a	_
9-7	1375-1378	key	_
9-8	1379-1386	genetic	_
9-9	1387-1396	modulator	_
9-10	1397-1400	for	_
9-11	1401-1407	heroin	_
9-12	1408-1421	vulnerability	_
9-13	1422-1424	by	_
9-14	1425-1434	affecting	_
9-15	1435-1438	the	_
9-16	1439-1450	connections	_
9-17	1451-1453	of	_
9-18	1454-1460	reward	_
9-19	1461-1468	network	_
9-20	1469-1472	and	_
9-21	1473-1482	cognition	_
9-22	1483-1484	.	_

10-1	1485-1488	The	_
10-2	1489-1493	role	_
10-3	1494-1496	of	_
10-4	1497-1500	the	_
10-5	1501-1507	reward	_
10-6	1508-1515	network	_
10-7	1516-1527	connections	_
10-8	1528-1532	that	_
10-9	1533-1541	mediates	_
10-10	1542-1545	the	_
10-11	1546-1553	effects	_
10-12	1554-1556	of	_
10-13	1557-1565	rs279858	_
10-14	1566-1568	on	_
10-15	1569-1578	cognition	_
10-16	1579-1584	would	_
10-17	1585-1587	be	_
10-18	1588-1597	disrupted	_
10-19	1598-1600	by	_
10-20	1601-1607	heroin	_
10-21	1608-1617	addiction	_
10-22	1618-1619	.	_

11-1	1620-1625	These	_
11-2	1626-1634	findings	_
11-3	1635-1642	provide	_
11-4	1643-1646	new	_
11-5	1647-1655	insights	_
11-6	1656-1660	into	_
11-7	1661-1664	the	_
11-8	1665-1679	neurocircuitry	_
11-9	1680-1683	and	_
11-10	1684-1691	genetic	_
11-11	1692-1702	mechanisms	_
11-12	1703-1705	of	_
11-13	1706-1715	addiction	_
11-14	1716-1717	.	_

12-1	1718-1725	Methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
12-2	1726-1729	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
12-3	1730-1739	materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
12-4	1740-1745	Study	_
12-5	1746-1752	design	_
12-6	1753-1757	Step	_
12-7	1758-1759	1	_
12-8	1760-1761	:	_
12-9	1762-1764	We	_
12-10	1765-1770	first	_
12-11	1771-1783	investigated	_
12-12	1784-1787	the	_
12-13	1788-1794	reward	_
12-14	1795-1802	network	_
12-15	1803-1810	changes	_
12-16	1811-1813	in	_
12-17	1814-1820	heroin	_
12-18	1821-1828	abusers	_
12-19	1829-1830	(	_
12-20	1831-1834	HAs	_
12-21	1835-1836	)	_
12-22	1837-1838	.	_

13-1	1839-1841	To	_
13-2	1842-1848	better	_
13-3	1849-1855	define	_
13-4	1856-1859	the	_
13-5	1860-1867	network	_
13-6	1868-1873	nodes	_
13-7	1874-1875	,	_
13-8	1876-1878	we	_
13-9	1879-1888	conducted	_
13-10	1889-1899	systematic	_
13-11	1900-1910	literature	_
13-12	1911-1917	review	_
13-13	1918-1921	and	_
13-14	1922-1932	identified	_
13-15	1933-1936	the	_
13-16	1937-1941	most	_
13-17	1942-1951	disrupted	_
13-18	1952-1957	brain	_
13-19	1958-1963	areas	_
13-20	1964-1967	for	_
13-21	1968-1977	rewarding	_
13-22	1978-1985	stimuli	_
13-23	1986-1988	in	_
13-24	1989-1998	substance	_
13-25	1999-2006	abusers	_
13-26	2007-2008	.	_

14-1	2009-2013	Then	_
14-2	2014-2017	the	_
14-3	2018-2024	reward	_
14-4	2025-2032	network	_
14-5	2033-2036	was	_
14-6	2037-2042	built	_
14-7	2043-2045	by	_
14-8	2046-2059	probabilistic	_
14-9	2060-2065	fiber	_
14-10	2066-2074	tracking	_
14-11	2075-2078	the	_
14-12	2079-2088	diffusion	http://maven.renci.org/NeuroBridge/neurobridge#DifffusionTensorImaging
14-13	2089-2095	tensor	http://maven.renci.org/NeuroBridge/neurobridge#DifffusionTensorImaging
14-14	2096-2103	imaging	http://maven.renci.org/NeuroBridge/neurobridge#DifffusionTensorImaging
14-15	2104-2105	(	http://maven.renci.org/NeuroBridge/neurobridge#DifffusionTensorImaging
14-16	2106-2109	DTI	http://maven.renci.org/NeuroBridge/neurobridge#DifffusionTensorImaging
14-17	2110-2111	)	http://maven.renci.org/NeuroBridge/neurobridge#DifffusionTensorImaging
14-18	2112-2116	data	_
14-19	2117-2121	from	_
14-20	2122-2124	78	_
14-21	2125-2128	HAs	_
14-22	2129-2132	and	_
14-23	2133-2135	79	_
14-24	2136-2143	healthy	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
14-25	2144-2152	controls	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
14-26	2153-2154	(	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
14-27	2155-2158	HCs	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
14-28	2159-2160	)	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
14-29	2161-2162	.	_

15-1	2163-2166	The	_
15-2	2167-2174	changes	_
15-3	2175-2177	in	_
15-4	2178-2185	network	_
15-5	2186-2201	characteristics	_
15-6	2202-2205	and	_
15-7	2206-2221	driving-control	_
15-8	2222-2233	subnetworks	_
15-9	2234-2238	were	_
15-10	2239-2248	estimated	_
15-11	2249-2250	.	_

16-1	2251-2255	Step	_
16-2	2256-2257	2	_
16-3	2258-2259	:	_
16-4	2260-2262	We	_
16-5	2263-2267	then	_
16-6	2268-2276	assessed	_
16-7	2277-2284	genetic	_
16-8	2285-2292	factors	_
16-9	2293-2297	that	_
16-10	2298-2301	may	_
16-11	2302-2310	modulate	_
16-12	2311-2318	changes	_
16-13	2319-2321	in	_
16-14	2322-2325	the	_
16-15	2326-2332	reward	_
16-16	2333-2340	network	_
16-17	2341-2343	in	_
16-18	2344-2347	HAs	_
16-19	2348-2350	by	_
16-20	2351-2361	performing	_
16-21	2362-2377	imaging-genetic	_
16-22	2378-2387	screening	_
16-23	2388-2391	for	_
16-24	2392-2394	22	_
16-25	2395-2412	addiction-related	_
16-26	2413-2426	polymorphisms	_
16-27	2427-2428	.	_

17-1	2429-2432	The	_
17-2	2433-2440	genetic	_
17-3	2441-2452	association	_
17-4	2453-2456	was	_
17-5	2457-2466	validated	_
17-6	2467-2469	by	_
17-7	2470-2480	performing	_
17-8	2481-2488	genetic	_
17-9	2489-2501	associations	_
17-10	2502-2503	(	_
17-11	2504-2508	1032	_
17-12	2509-2512	HAs	_
17-13	2513-2516	and	_
17-14	2517-2521	2863	_
17-15	2522-2525	HCs	_
17-16	2526-2527	)	_
17-17	2528-2531	and	_
17-18	2532-2548	expanded-variant	_
17-19	2549-2557	analysis	_
17-20	2558-2559	.	_

18-1	2560-2564	Step	_
18-2	2565-2566	3	_
18-3	2567-2568	:	_
18-4	2569-2576	Finally	_
18-5	2577-2578	,	_
18-6	2579-2582	the	_
18-7	2583-2594	association	_
18-8	2595-2602	between	_
18-9	2603-2606	the	_
18-10	2607-2614	genetic	_
18-11	2615-2624	variation	_
18-12	2625-2626	,	_
18-13	2627-2634	changes	_
18-14	2635-2637	in	_
18-15	2638-2644	reward	_
18-16	2645-2652	network	_
18-17	2653-2654	,	_
18-18	2655-2658	and	_
18-19	2659-2667	clinical	_
18-20	2668-2679	performance	_
18-21	2680-2683	was	_
18-22	2684-2692	analyzed	_
18-23	2693-2695	by	_
18-24	2696-2705	mediation	_
18-25	2706-2714	analysis	_
18-26	2715-2716	.	_

19-1	2717-2727	Systematic	_
19-2	2728-2734	review	_
19-3	2735-2737	of	_
19-4	2738-2745	imaging	_
19-5	2746-2753	studies	_
19-6	2754-2757	The	_
19-7	2758-2768	systematic	_
19-8	2769-2779	literature	_
19-9	2780-2786	review	_
19-10	2787-2790	was	_
19-11	2791-2800	conducted	_
19-12	2801-2803	to	_
19-13	2804-2808	help	_
19-14	2809-2817	identify	_
19-15	2818-2827	disrupted	_
19-16	2828-2842	reward-related	_
19-17	2843-2848	brain	_
19-18	2849-2856	regions	_
19-19	2857-2862	which	_
19-20	2863-2872	responses	_
19-21	2873-2875	to	_
19-22	2876-2885	rewarding	_
19-23	2886-2893	stimuli	_
19-24	2894-2895	(	_
19-25	2896-2913	substance-related	_
19-26	2914-2921	stimuli	_
19-27	2922-2923	,	_
19-28	2924-2932	monetary	_
19-29	2933-2940	rewards	_
19-30	2941-2942	,	_
19-31	2943-2946	and	_
19-32	2947-2952	happy	_
19-33	2953-2961	feelings	_
19-34	2962-2963	)	_
19-35	2964-2966	in	_
19-36	2967-2976	substance	_
19-37	2977-2984	abusers	_
19-38	2985-2986	.	_

20-1	2987-2990	The	_
20-2	2991-2997	search	_
20-3	2998-3003	terms	_
20-4	3004-3012	included	_
20-5	3013-3025	neuroimaging	_
20-6	3026-3031	terms	_
20-7	3032-3033	,	_
20-8	3034-3043	substance	_
20-9	3044-3061	addiction-related	_
20-10	3062-3067	terms	_
20-11	3068-3069	,	_
20-12	3070-3073	and	_
20-13	3074-3090	stimulus-related	_
20-14	3091-3096	terms	_
20-15	3097-3098	.	_

21-1	3099-3102	The	_
21-2	3103-3108	focus	_
21-3	3109-3111	of	_
21-4	3112-3115	the	_
21-5	3116-3123	studies	_
21-6	3124-3132	selected	_
21-7	3133-3136	for	_
21-8	3137-3140	the	_
21-9	3141-3151	systematic	_
21-10	3152-3158	review	_
21-11	3159-3162	was	_
21-12	3163-3165	on	_
21-13	3166-3169	the	_
21-14	3170-3181	comparisons	_
21-15	3182-3189	between	_
21-16	3190-3199	substance	_
21-17	3200-3207	abusers	_
21-18	3208-3211	and	_
21-19	3212-3215	HCs	_
21-20	3216-3219	and	_
21-21	3220-3231	whole-brain	_
21-22	3232-3240	analysis	_
21-23	3241-3242	,	_
21-24	3243-3248	which	_
21-25	3249-3252	was	_
21-26	3253-3262	published	_
21-27	3263-3269	online	_
21-28	3270-3276	before	_
21-29	3277-3279	30	_
21-30	3280-3288	November	_
21-31	3289-3293	2016	_
21-32	3294-3295	.	_

22-1	3296-3298	We	_
22-2	3299-3309	identified	_
22-3	3310-3311	a	_
22-4	3312-3317	total	_
22-5	3318-3320	of	_
22-6	3321-3323	65	_
22-7	3324-3331	studies	_
22-8	3332-3335	and	_
22-9	3336-3345	organized	_
22-10	3346-3349	the	_
22-11	3350-3358	findings	_
22-12	3359-3361	by	_
22-13	3362-3370	specific	_
22-14	3371-3376	brain	_
22-15	3377-3384	regions	_
22-16	3385-3386	(	_
22-17	3387-3392	Table	_
22-18	3393-3395	S1	_
22-19	3396-3397	)	_
22-20	3398-3399	.	_

23-1	3400-3403	The	_
23-2	3404-3410	search	_
23-3	3411-3419	strategy	_
23-4	3420-3422	is	_
23-5	3423-3431	detailed	_
23-6	3432-3434	in	_
23-7	3435-3438	the	_
23-8	3439-3452	Supplementary	_
23-9	3453-3462	Materials	_
23-10	3463-3464	.	_

24-1	3465-3473	Subjects	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
24-2	3474-3477	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
24-3	3478-3483	group	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
24-4	3484-3485	A	_
24-5	3486-3492	cohort	_
24-6	3493-3495	of	_
24-7	3496-3498	78	_
24-8	3499-3503	male	_
24-9	3504-3507	HAs	http://maven.renci.org/NeuroBridge/neurobridge#BiphasicAlcoholEffectsScale
24-10	3508-3511	was	_
24-11	3512-3521	recruited	_
24-12	3522-3526	from	_
24-13	3527-3531	drug	_
24-14	3532-3541	addiction	_
24-15	3542-3551	treatment	_
24-16	3552-3559	centers	_
24-17	3560-3563	and	_
24-18	3564-3567	the	_
24-19	3568-3573	local	_
24-20	3574-3583	community	_
24-21	3584-3586	in	_
24-22	3587-3596	Zhongshan	_
24-23	3597-3601	city	_
24-24	3602-3603	,	_
24-25	3604-3613	Guangdong	_
24-26	3614-3622	province	_
24-27	3623-3624	,	_
24-28	3625-3630	China	_
24-29	3631-3632	.	_

25-1	3633-3637	They	_
25-2	3638-3641	all	_
25-3	3642-3645	met	_
25-4	3646-3649	the	_
25-5	3650-3658	criteria	_
25-6	3659-3662	for	_
25-7	3663-3669	heroin	_
25-8	3670-3680	dependence	_
25-9	3681-3686	based	_
25-10	3687-3689	on	_
25-11	3690-3693	the	_
25-12	3694-3704	Diagnostic	_
25-13	3705-3708	and	_
25-14	3709-3720	Statistical	_
25-15	3721-3727	Manual	_
25-16	3728-3730	of	_
25-17	3731-3737	Mental	_
25-18	3738-3747	Disorders	_
25-19	3748-3749	,	_
25-20	3750-3753	4th	_
25-21	3754-3761	edition	_
25-22	3762-3763	,	_
25-23	3764-3767	but	_
25-24	3768-3771	not	_
25-25	3772-3775	for	_
25-26	3776-3781	other	_
25-27	3782-3792	substances	_
25-28	3793-3794	(	_
25-29	3795-3799	i.e.	_
25-30	3800-3801	,	_
25-31	3802-3805	use	_
25-32	3806-3808	of	_
25-33	3809-3814	other	_
25-34	3815-3822	opioids	_
25-35	3823-3826	for	_
25-36	3827-3830	not	_
25-37	3831-3835	more	_
25-38	3836-3840	than	_
25-39	3841-3842	1	_
25-40	3843-3848	month	_
25-41	3849-3852	and	_
25-42	3853-3858	other	_
25-43	3859-3864	types	_
25-44	3865-3867	of	_
25-45	3868-3877	addictive	_
25-46	3878-3883	drugs	_
25-47	3884-3887	for	_
25-48	3888-3891	not	_
25-49	3892-3896	more	_
25-50	3897-3901	than	_
25-51	3902-3907	three	_
25-52	3908-3913	times	_
25-53	3914-3917	per	_
25-54	3918-3922	year	_
25-55	3923-3924	,	_
25-56	3925-3929	with	_
25-57	3930-3933	the	_
25-58	3934-3943	exception	_
25-59	3944-3946	of	_
25-60	3947-3955	nicotine	_
25-61	3956-3957	)	_
25-62	3958-3959	.	_

26-1	3960-3967	Alcohol	_
26-2	3968-3975	abusers	_
26-3	3976-3980	were	_
26-4	3981-3989	excluded	_
26-5	3990-3994	from	_
26-6	3995-3998	the	_
26-7	3999-4004	study	_
26-8	4005-4010	based	_
26-9	4011-4013	on	_
26-10	4014-4017	the	_
26-11	4018-4026	Michigan	_
26-12	4027-4037	Alcoholism	_
26-13	4038-4047	Screening	_
26-14	4048-4052	Test	_
26-15	4053-4054	(	_
26-16	4055-4060	score	_
26-17	4061-4062	≤	_
26-18	4063-4064	4	_
26-19	4065-4066	)	_
26-20	4067-4068	.	_

27-1	4069-4071	In	_
27-2	4072-4080	addition	_
27-3	4081-4082	,	_
27-4	4083-4085	we	_
27-5	4086-4095	recruited	_
27-6	4096-4098	79	_
27-7	4099-4106	matched	_
27-8	4107-4111	male	_
27-9	4112-4115	HCs	http://maven.renci.org/NeuroBridge/neurobridge#Thing
27-10	4116-4120	from	_
27-11	4121-4124	the	_
27-12	4125-4130	local	_
27-13	4131-4140	community	_
27-14	4141-4148	through	_
27-15	4149-4158	newspaper	_
27-16	4159-4173	advertisements	_
27-17	4174-4175	.	_

28-1	4176-4179	All	_
28-2	4180-4182	of	_
28-3	4183-4186	the	_
28-4	4187-4199	participants	_
28-5	4200-4204	were	_
28-6	4205-4211	ethnic	_
28-7	4212-4215	Han	_
28-8	4216-4223	Chinese	_
28-9	4224-4225	,	_
28-10	4226-4229	and	_
28-11	4230-4236	native	_
28-12	4237-4239	to	_
28-13	4240-4248	southern	_
28-14	4249-4254	China	_
28-15	4255-4256	.	_

29-1	4257-4260	The	_
29-2	4261-4264	HAs	http://maven.renci.org/NeuroBridge/neurobridge#BiphasicAlcoholEffectsScale
29-3	4265-4278	self-reported	_
29-4	4279-4283	that	_
29-5	4284-4288	they	_
29-6	4289-4292	had	_
29-7	4293-4295	no	_
29-8	4296-4300	past	_
29-9	4301-4303	or	_
29-10	4304-4311	current	_
29-11	4312-4317	major	_
29-12	4318-4325	medical	_
29-13	4326-4336	conditions	_
29-14	4337-4340	and	_
29-15	4341-4343	no	_
29-16	4344-4352	personal	_
29-17	4353-4355	or	_
29-18	4356-4362	family	_
29-19	4363-4370	history	_
29-20	4371-4373	of	_
29-21	4374-4379	major	_
29-22	4380-4391	psychiatric	_
29-23	4392-4401	disorders	_
29-24	4402-4407	other	_
29-25	4408-4412	than	_
29-26	4413-4418	their	_
29-27	4419-4426	current	_
29-28	4427-4436	addiction	_
29-29	4437-4438	.	_

30-1	4439-4442	The	_
30-2	4443-4452	exclusion	_
30-3	4453-4461	criteria	_
30-4	4462-4470	included	_
30-5	4471-4472	(	_
30-6	4473-4474	1	_
30-7	4475-4476	)	_
30-8	4477-4482	level	_
30-9	4483-4485	of	_
30-10	4486-4495	education	_
30-11	4496-4497	<	_
30-12	4498-4499	9	_
30-13	4500-4505	years	_
30-14	4506-4507	,	_
30-15	4508-4509	(	_
30-16	4510-4511	2	_
30-17	4512-4513	)	_
30-18	4514-4525	left-handed	_
30-19	4526-4527	,	_
30-20	4528-4531	and	_
30-21	4532-4533	(	_
30-22	4534-4535	3	_
30-23	4536-4537	)	_
30-24	4538-4555	contraindications	_
30-25	4556-4559	for	_
30-26	4560-4568	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
30-27	4569-4578	resonance	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
30-28	4579-4586	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
30-29	4587-4588	(	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
30-30	4589-4592	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
30-31	4593-4594	)	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
30-32	4595-4596	.	_

31-1	4597-4604	Genetic	_
31-2	4605-4615	validation	_
31-3	4616-4621	group	_
31-4	4622-4625	The	_
31-5	4626-4633	genetic	_
31-6	4634-4644	validation	_
31-7	4645-4652	dataset	_
31-8	4653-4661	included	_
31-9	4662-4666	1032	_
31-10	4667-4670	HAs	_
31-11	4671-4672	(	_
31-12	4673-4676	725	_
31-13	4677-4682	males	_
31-14	4683-4684	,	_
31-15	4685-4688	307	_
31-16	4689-4696	females	_
31-17	4697-4698	)	_
31-18	4699-4700	,	_
31-19	4701-4704	who	_
31-20	4705-4709	were	_
31-21	4710-4719	recruited	_
31-22	4720-4724	from	_
31-23	4725-4733	multiple	_
31-24	4734-4738	drug	_
31-25	4739-4748	addiction	_
31-26	4749-4758	treatment	_
31-27	4759-4766	centers	_
31-28	4767-4769	in	_
31-29	4770-4779	Guangdong	_
31-30	4780-4783	and	_
31-31	4784-4789	Hubei	_
31-32	4790-4799	provinces	_
31-33	4800-4803	and	_
31-34	4804-4808	2863	_
31-35	4809-4812	HCs	_
31-36	4813-4814	(	_
31-37	4815-4819	1303	_
31-38	4820-4824	male	_
31-39	4825-4826	,	_
31-40	4827-4831	1560	_
31-41	4832-4838	female	_
31-42	4839-4840	)	_
31-43	4841-4845	from	_
31-44	4846-4849	the	_
31-45	4850-4860	respective	_
31-46	4861-4866	local	_
31-47	4867-4878	communities	_
31-48	4879-4880	.	_

32-1	4881-4884	The	_
32-2	4885-4888	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
32-3	4889-4894	group	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
32-4	4895-4898	was	_
32-5	4899-4900	a	_
32-6	4901-4910	subsample	_
32-7	4911-4916	group	_
32-8	4917-4924	derived	_
32-9	4925-4929	from	_
32-10	4930-4933	the	_
32-11	4934-4941	genetic	_
32-12	4942-4948	sample	_
32-13	4949-4954	group	_
32-14	4955-4956	(	_
32-15	4957-4961	only	_
32-16	4962-4966	from	_
32-17	4967-4976	Zhongshan	_
32-18	4977-4981	city	_
32-19	4982-4983	)	_
32-20	4984-4985	.	_

33-1	4986-4989	The	_
33-2	4990-5005	characteristics	_
33-3	5006-5008	of	_
33-4	5009-5012	the	_
33-5	5013-5021	subjects	_
33-6	5022-5025	are	_
33-7	5026-5036	summarized	_
33-8	5037-5039	in	_
33-9	5040-5045	Table	_
33-10	5046-5047	1	_
33-11	5048-5049	.	_

34-1	5050-5053	The	_
34-2	5054-5059	study	_
34-3	5060-5063	was	_
34-4	5064-5072	approved	_
34-5	5073-5075	by	_
34-6	5076-5079	the	_
34-7	5080-5086	Peking	_
34-8	5087-5097	University	_
34-9	5098-5111	Institutional	_
34-10	5112-5118	Review	_
34-11	5119-5124	Board	_
34-12	5125-5126	.	_

35-1	5127-5130	All	_
35-2	5131-5139	subjects	_
35-3	5140-5144	were	_
35-4	5145-5153	informed	_
35-5	5154-5156	of	_
35-6	5157-5160	the	_
35-7	5161-5167	entire	_
35-8	5168-5177	procedure	_
35-9	5178-5181	and	_
35-10	5182-5191	potential	_
35-11	5192-5197	risks	_
35-12	5198-5204	before	_
35-13	5205-5210	being	_
35-14	5211-5220	requested	_
35-15	5221-5223	to	_
35-16	5224-5228	sign	_
35-17	5229-5230	a	_
35-18	5231-5238	written	_
35-19	5239-5247	informed	_
35-20	5248-5255	consent	_
35-21	5256-5260	form	_
35-22	5261-5262	.	_

36-1	5263-5266	All	_
36-2	5267-5279	participants	_
36-3	5280-5288	received	_
36-4	5289-5297	monetary	_
36-5	5298-5310	compensation	_
36-6	5311-5314	for	_
36-7	5315-5327	contributing	_
36-8	5328-5330	to	_
36-9	5331-5334	the	_
36-10	5335-5340	study	_
36-11	5341-5342	.	_

37-1	5343-5347	None	_
37-2	5348-5350	of	_
37-3	5351-5354	HAs	_
37-4	5355-5363	received	_
37-5	5364-5372	systemic	_
37-6	5373-5388	pharmacological	_
37-7	5389-5401	substitution	_
37-8	5402-5412	treatments	_
37-9	5413-5419	during	_
37-10	5420-5424	this	_
37-11	5425-5430	study	_
37-12	5431-5432	.	_

38-1	5433-5447	Neurocognitive	_
38-2	5448-5451	and	_
38-3	5452-5462	behavioral	_
38-4	5463-5474	assessments	_
38-5	5475-5478	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
38-6	5479-5487	subjects	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
38-7	5488-5497	underwent	_
38-8	5498-5499	a	_
38-9	5500-5508	detailed	_
38-10	5509-5515	series	_
38-11	5516-5518	of	_
38-12	5519-5531	standardized	_
38-13	5532-5550	neuropsychological	_
38-14	5551-5556	tests	_
38-15	5557-5558	,	_
38-16	5559-5565	either	_
38-17	5566-5568	on	_
38-18	5569-5572	the	_
38-19	5573-5577	same	_
38-20	5578-5581	day	_
38-21	5582-5584	or	_
38-22	5585-5591	within	_
38-23	5592-5593	7	_
38-24	5594-5598	days	_
38-25	5599-5601	of	_
38-26	5602-5605	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
38-27	5606-5611	scans	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
38-28	5612-5613	.	_

39-1	5614-5618	This	_
39-2	5619-5627	included	_
39-3	5628-5629	(	_
39-4	5630-5631	1	_
39-5	5632-5633	)	_
39-6	5634-5637	the	_
39-7	5638-5646	Montreal	_
39-8	5647-5656	Cognitive	http://maven.renci.org/NeuroBridge/neurobridge#TheMontrealCognitiveAssessment
39-9	5657-5667	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#TheMontrealCognitiveAssessment
39-10	5668-5669	(	http://maven.renci.org/NeuroBridge/neurobridge#TheMontrealCognitiveAssessment
39-11	5670-5674	MoCA	http://maven.renci.org/NeuroBridge/neurobridge#TheMontrealCognitiveAssessment
39-12	5675-5676	)	http://maven.renci.org/NeuroBridge/neurobridge#TheMontrealCognitiveAssessment
39-13	5677-5679	to	_
39-14	5680-5686	assess	_
39-15	5687-5693	global	_
39-16	5694-5703	cognitive	_
39-17	5704-5711	ability	_
39-18	5712-5713	,	_
39-19	5714-5715	(	_
39-20	5716-5717	2	_
39-21	5718-5719	)	_
39-22	5720-5723	the	_
39-23	5724-5731	Barratt	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
39-24	5732-5745	Impulsiveness	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
39-25	5746-5751	Scale	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
39-26	5752-5753	(	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
39-27	5754-5760	BIS-11	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
39-28	5761-5762	)	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
39-29	5763-5765	to	_
39-30	5766-5775	determine	_
39-31	5776-5779	the	_
39-32	5780-5785	level	_
39-33	5786-5788	of	_
39-34	5789-5800	impulsivity	_
39-35	5801-5802	,	_
39-36	5803-5804	(	_
39-37	5805-5806	3	_
39-38	5807-5808	)	_
39-39	5809-5812	the	_
39-40	5813-5817	Iowa	http://maven.renci.org/NeuroBridge/neurobridge#PathologicalGambling
39-41	5818-5826	Gambling	http://maven.renci.org/NeuroBridge/neurobridge#PathologicalGambling
39-42	5827-5831	Task	http://maven.renci.org/NeuroBridge/neurobridge#PathologicalGambling
39-43	5832-5833	(	http://maven.renci.org/NeuroBridge/neurobridge#PathologicalGambling
39-44	5834-5837	IGT	http://maven.renci.org/NeuroBridge/neurobridge#PathologicalGambling
39-45	5838-5839	)	http://maven.renci.org/NeuroBridge/neurobridge#PathologicalGambling
39-46	5840-5842	to	_
39-47	5843-5851	evaluate	_
39-48	5852-5867	decision-making	_
39-49	5868-5875	ability	_
39-50	5876-5877	,	_
39-51	5878-5881	and	_
39-52	5882-5883	(	_
39-53	5884-5885	4	_
39-54	5886-5887	)	_
39-55	5888-5889	a	_
39-56	5890-5896	visual	_
39-57	5897-5903	analog	http://maven.renci.org/NeuroBridge/neurobridge#Scale
39-58	5904-5909	scale	http://maven.renci.org/NeuroBridge/neurobridge#Scale
39-59	5910-5912	to	_
39-60	5913-5919	assess	_
39-61	5920-5933	self-reported	_
39-62	5934-5941	average	_
39-63	5942-5948	heroin	_
39-64	5949-5956	craving	_
39-65	5957-5963	during	_
39-66	5964-5967	the	_
39-67	5968-5972	past	_
39-68	5973-5977	week	_
39-69	5978-5979	.	_

40-1	5980-5988	Detailed	_
40-2	5989-6001	descriptions	_
40-3	6002-6004	of	_
40-4	6005-6010	these	_
40-5	6011-6022	assessments	_
40-6	6023-6026	are	_
40-7	6027-6036	available	_
40-8	6037-6039	in	_
40-9	6040-6043	the	_
40-10	6044-6057	Supplementary	_
40-11	6058-6067	Materials	_
40-12	6068-6069	.	_

41-1	6070-6073	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
41-2	6074-6078	data	_
41-3	6079-6090	acquisition	_
41-4	6091-6094	and	_
41-5	6095-6108	preprocessing	_
41-6	6109-6112	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
41-7	6113-6116	was	_
41-8	6117-6126	performed	_
41-9	6127-6132	using	_
41-10	6133-6134	a	_
41-11	6135-6140	1.5-T	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
41-12	6141-6143	MR	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
41-13	6144-6149	Signa	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
41-14	6150-6154	HDxt	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
41-15	6155-6162	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
41-16	6163-6169	system	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
41-17	6170-6171	(	_
41-18	6172-6179	General	_
41-19	6180-6188	Electric	_
41-20	6189-6196	Medical	_
41-21	6197-6203	System	_
41-22	6204-6205	,	_
41-23	6206-6215	Milwaukee	_
41-24	6216-6217	,	_
41-25	6218-6220	WI	_
41-26	6221-6222	,	_
41-27	6223-6226	USA	_
41-28	6227-6228	)	_
41-29	6229-6233	with	_
41-30	6234-6235	a	_
41-31	6236-6244	standard	_
41-32	6245-6258	eight-channel	_
41-33	6259-6263	head	_
41-34	6264-6268	coil	_
41-35	6269-6270	.	_

42-1	6271-6274	Two	_
42-2	6275-6286	experienced	_
42-3	6287-6299	radiologists	_
42-4	6300-6308	examined	_
42-5	6309-6312	the	_
42-6	6313-6315	T2	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
42-7	6316-6322	images	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
42-8	6323-6324	,	_
42-9	6325-6328	and	_
42-10	6329-6331	no	_
42-11	6332-6345	abnormalities	_
42-12	6346-6350	were	_
42-13	6351-6359	observed	_
42-14	6360-6362	in	_
42-15	6363-6366	the	_
42-16	6367-6375	subjects	_
42-17	6376-6377	.	_

43-1	6378-6389	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
43-2	6390-6398	sagittal	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
43-3	6399-6416	three-dimensional	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
43-4	6417-6423	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
43-5	6424-6428	were	_
43-6	6429-6437	acquired	_
43-7	6438-6442	with	_
43-8	6443-6444	a	_
43-9	6445-6452	spoiled	_
43-10	6453-6461	gradient	_
43-11	6462-6470	recalled	_
43-12	6471-6475	echo	_
43-13	6476-6484	sequence	_
43-14	6485-6489	with	_
43-15	6490-6498	coverage	_
43-16	6499-6501	of	_
43-17	6502-6505	the	_
43-18	6506-6512	entire	_
43-19	6513-6518	brain	_
43-20	6519-6520	.	_

44-1	6521-6524	For	_
44-2	6525-6528	DTI	http://maven.renci.org/NeuroBridge/neurobridge#DifffusionTensorImaging
44-3	6529-6530	,	_
44-4	6531-6532	a	_
44-5	6533-6538	total	_
44-6	6539-6541	of	_
44-7	6542-6544	28	_
44-8	6545-6550	image	_
44-9	6551-6555	sets	_
44-10	6556-6559	was	_
44-11	6560-6568	acquired	_
44-12	6569-6573	with	_
44-13	6574-6576	56	_
44-14	6577-6582	axial	_
44-15	6583-6589	slices	_
44-16	6590-6591	(	_
44-17	6592-6597	slice	_
44-18	6598-6607	thickness	_
44-19	6608-6609	:	_
44-20	6610-6613	2.4	_
44-21	6614-6616	mm	_
44-22	6617-6621	with	_
44-23	6622-6624	no	_
44-24	6625-6628	gap	_
44-25	6629-6630	;	_
44-26	6631-6641	repetition	_
44-27	6642-6651	time/echo	_
44-28	6652-6656	time	_
44-29	6657-6658	:	_
44-30	6659-6663	14.4	_
44-31	6664-6668	s/85	_
44-32	6669-6671	ms	_
44-33	6672-6673	;	_
44-34	6674-6675	3	_
44-35	6676-6678	b0	_
44-36	6679-6685	images	_
44-37	6686-6693	without	_
44-38	6694-6703	diffusion	_
44-39	6704-6713	weighting	_
44-40	6714-6715	;	_
44-41	6716-6718	25	_
44-42	6719-6732	non-collinear	_
44-43	6733-6752	diffusion-weighting	_
44-44	6753-6762	gradients	_
44-45	6763-6767	with	_
44-46	6768-6769	b	_
44-47	6770-6771	=	_
44-48	6772-6776	1000	_
44-49	6777-6782	s/mm2	_
44-50	6783-6784	;	_
44-51	6785-6796	acquisition	_
44-52	6797-6803	matrix	_
44-53	6804-6805	:	_
44-54	6806-6809	128	_
44-55	6810-6811	×	_
44-56	6812-6815	128	_
44-57	6816-6817	;	_
44-58	6818-6823	field	_
44-59	6824-6826	of	_
44-60	6827-6831	view	_
44-61	6832-6833	:	_
44-62	6834-6837	256	_
44-63	6838-6839	×	_
44-64	6840-6843	256	_
44-65	6844-6847	mm2	_
44-66	6848-6849	)	_
44-67	6850-6851	.	_

45-1	6852-6855	The	_
45-2	6856-6859	DTI	_
45-3	6860-6864	data	_
45-4	6865-6869	were	_
45-5	6870-6882	preprocessed	_
45-6	6883-6888	using	_
45-7	6889-6897	FSL5.0.7	_
45-8	6898-6899	(	_
45-9	6900-6923	www.fmrib.ox.ac.uk/fsl/	_
45-10	6924-6925	;	_
45-11	6926-6934	accessed	_
45-12	6935-6936	6	_
45-13	6937-6946	September	_
45-14	6947-6951	2017	_
45-15	6952-6953	)	_
45-16	6954-6959	using	_
45-17	6960-6963	the	_
45-18	6964-6973	following	_
45-19	6974-6979	steps	_
45-20	6980-6981	:	_
45-21	6982-6983	(	_
45-22	6984-6985	1	_
45-23	6986-6987	)	_
45-24	6988-7000	Eddy-current	_
45-25	7001-7004	and	_
45-26	7005-7009	head	_
45-27	7010-7016	motion	_
45-28	7017-7027	correction	_
45-29	7028-7029	,	_
45-30	7030-7040	estimation	_
45-31	7041-7043	of	_
45-32	7044-7047	the	_
45-33	7048-7057	diffusion	_
45-34	7058-7065	tensors	_
45-35	7066-7067	,	_
45-36	7068-7071	and	_
45-37	7072-7083	calculation	_
45-38	7084-7086	of	_
45-39	7087-7097	functional	_
45-40	7098-7108	anisotropy	_
45-41	7109-7110	(	_
45-42	7111-7113	FA	_
45-43	7114-7115	)	_
45-44	7116-7117	;	_
45-45	7118-7119	(	_
45-46	7120-7121	2	_
45-47	7122-7123	)	_
45-48	7124-7139	co-registration	_
45-49	7140-7142	of	_
45-50	7143-7145	T1	_
45-51	7146-7151	scans	_
45-52	7152-7156	with	_
45-53	7157-7162	their	_
45-54	7163-7176	corresponding	_
45-55	7177-7180	DTI	_
45-56	7181-7183	b0	_
45-57	7184-7189	image	_
45-58	7190-7192	so	_
45-59	7193-7197	that	_
45-60	7198-7202	ROIs	_
45-61	7203-7207	that	_
45-62	7208-7212	were	_
45-63	7213-7220	defined	_
45-64	7221-7223	in	_
45-65	7224-7227	the	_
45-66	7228-7238	structural	_
45-67	7239-7242	MRI	_
45-68	7243-7248	space	_
45-69	7249-7254	could	_
45-70	7255-7257	be	_
45-71	7258-7269	transformed	_
45-72	7270-7274	into	_
45-73	7275-7281	native	_
45-74	7282-7291	diffusion	_
45-75	7292-7297	space	_
45-76	7298-7299	;	_
45-77	7300-7301	(	_
45-78	7302-7303	3	_
45-79	7304-7305	)	_
45-80	7306-7309	the	_
45-81	7310-7312	FA	_
45-82	7313-7319	images	_
45-83	7320-7324	were	_
45-84	7325-7334	spatially	_
45-85	7335-7345	normalized	_
45-86	7346-7348	to	_
45-87	7349-7352	the	_
45-88	7353-7361	Montreal	_
45-89	7362-7374	Neurological	_
45-90	7375-7384	Institute	_
45-91	7385-7386	(	_
45-92	7387-7390	MNI	_
45-93	7391-7392	)	_
45-94	7393-7398	space	_
45-95	7399-7404	using	_
45-96	7405-7411	DARTEL	_
45-97	7412-7414	of	_
45-98	7415-7419	SPM8	_
45-99	7420-7421	,	_
45-100	7422-7431	resampled	_
45-101	7432-7434	to	_
45-102	7435-7436	3	_
45-103	7437-7438	×	_
45-104	7439-7440	3	_
45-105	7441-7442	×	_
45-106	7443-7444	3	_
45-107	7445-7448	mm3	_
45-108	7449-7455	during	_
45-109	7456-7459	the	_
45-110	7460-7473	normalization	_
45-111	7474-7475	,	_
45-112	7476-7479	and	_
45-113	7480-7488	smoothed	_
45-114	7489-7493	with	_
45-115	7494-7496	an	_
45-116	7497-7501	6-mm	_
45-117	7502-7512	full-width	_
45-118	7513-7515	at	_
45-119	7516-7528	half-maximum	_
45-120	7529-7537	Gaussian	_
45-121	7538-7544	kernel	_
45-122	7545-7546	.	_

46-1	7547-7554	Network	_
46-2	7555-7567	construction	_
46-3	7568-7571	The	_
46-4	7572-7576	flow	_
46-5	7577-7582	chart	_
46-6	7583-7585	of	_
46-7	7586-7593	network	_
46-8	7594-7602	analysis	_
46-9	7603-7606	was	_
46-10	7607-7612	shown	_
46-11	7613-7615	in	_
46-12	7616-7619	Fig	_
46-13	7620-7621	.	_

47-1	7622-7624	S1	_
47-2	7625-7626	.	_

48-1	7627-7634	Network	_
48-2	7635-7640	nodes	_
48-3	7641-7651	definition	_
48-4	7652-7654	We	_
48-5	7655-7662	defined	_
48-6	7663-7666	the	_
48-7	7667-7676	addiction	_
48-8	7677-7691	reward-related	_
48-9	7692-7697	brain	_
48-10	7698-7705	regions	_
48-11	7706-7707	(	_
48-12	7708-7710	12	_
48-13	7711-7718	regions	_
48-14	7719-7721	in	_
48-15	7722-7726	each	_
48-16	7727-7737	hemisphere	_
48-17	7738-7739	)	_
48-18	7740-7741	,	_
48-19	7742-7747	which	_
48-20	7748-7752	were	_
48-21	7753-7757	both	_
48-22	7758-7764	highly	_
48-23	7765-7773	reported	_
48-24	7774-7776	in	_
48-25	7777-7780	our	_
48-26	7781-7791	systematic	_
48-27	7792-7802	literature	_
48-28	7803-7809	review	_
48-29	7810-7813	and	_
48-30	7814-7822	involved	_
48-31	7823-7825	in	_
48-32	7826-7836	biological	_
48-33	7837-7846	mechanism	_
48-34	7847-7849	of	_
48-35	7850-7856	heroin	_
48-36	7857-7866	addiction	_
48-37	7867-7868	,	_
48-38	7869-7871	as	_
48-39	7872-7875	the	_
48-40	7876-7881	nodes	_
48-41	7882-7884	of	_
48-42	7885-7891	reward	_
48-43	7892-7899	network	_
48-44	7900-7901	.	_

49-1	7902-7907	These	_
49-2	7908-7916	involved	_
49-3	7917-7920	the	_
49-4	7921-7926	dlPFC	_
49-5	7927-7928	,	_
49-6	7929-7932	ACC	_
49-7	7933-7934	,	_
49-8	7935-7938	VTA	_
49-9	7939-7940	,	_
49-10	7941-7954	orbitofrontal	_
49-11	7955-7961	cortex	_
49-12	7962-7963	(	_
49-13	7964-7967	OFC	_
49-14	7968-7969	)	_
49-15	7970-7971	,	_
49-16	7972-7978	insula	_
49-17	7979-7980	(	_
49-18	7981-7984	INS	_
49-19	7985-7986	)	_
49-20	7987-7988	,	_
49-21	7989-7996	ventral	_
49-22	7997-8005	striatum	_
49-23	8006-8007	(	_
49-24	8008-8012	VStr	_
49-25	8013-8014	)	_
49-26	8015-8016	,	_
49-27	8017-8024	caudate	_
49-28	8025-8026	,	_
49-29	8027-8035	amygdala	_
49-30	8036-8037	(	_
49-31	8038-8041	AMY	_
49-32	8042-8043	)	_
49-33	8044-8045	,	_
49-34	8046-8057	hippocampus	_
49-35	8058-8059	(	_
49-36	8060-8063	HIP	_
49-37	8064-8065	)	_
49-38	8066-8067	,	_
49-39	8068-8076	thalamus	_
49-40	8077-8078	(	_
49-41	8079-8082	THA	_
49-42	8083-8084	)	_
49-43	8085-8086	,	_
49-44	8087-8094	putamen	_
49-45	8095-8096	,	_
49-46	8097-8100	and	_
49-47	8101-8109	pallidum	_
49-48	8110-8111	(	_
49-49	8112-8123	definitions	_
49-50	8124-8127	are	_
49-51	8128-8137	indicated	_
49-52	8138-8140	in	_
49-53	8141-8146	Table	_
49-54	8147-8149	S2	_
49-55	8150-8153	and	_
49-56	8154-8157	Fig	_
49-57	8158-8159	.	_

50-1	8160-8162	1a	_
50-2	8163-8164	)	_
50-3	8165-8166	.	_

51-1	8167-8179	Specifically	_
51-2	8180-8181	,	_
51-3	8182-8184	we	_
51-4	8185-8192	defined	_
51-5	8193-8196	the	_
51-6	8197-8208	subnetworks	_
51-7	8209-8214	based	_
51-8	8215-8217	on	_
51-9	8218-8231	authoritative	_
51-10	8232-8239	reviews	_
51-11	8240-8241	,	_
51-12	8242-8245	the	_
51-13	8246-8260	reward-driving	_
51-14	8261-8271	subnetwork	_
51-15	8272-8281	comprised	_
51-16	8282-8285	the	_
51-17	8286-8289	VTA	_
51-18	8290-8291	,	_
51-19	8292-8295	NAc	_
51-20	8296-8297	,	_
51-21	8298-8301	AMY	_
51-22	8302-8303	,	_
51-23	8304-8307	THA	_
51-24	8308-8309	,	_
51-25	8310-8313	and	_
51-26	8314-8319	other	_
51-27	8320-8331	subcortical	_
51-28	8332-8339	regions	_
51-29	8340-8344	that	_
51-30	8345-8354	responded	_
51-31	8355-8357	to	_
51-32	8358-8367	impulsive	_
51-33	8368-8378	motivation	_
51-34	8379-8386	driving	_
51-35	8387-8389	of	_
51-36	8390-8399	substance	_
51-37	8400-8406	reward	_
51-38	8407-8408	(	_
51-39	8409-8413	e.g.	_
51-40	8414-8415	,	_
51-41	8416-8423	craving	_
51-42	8424-8425	)	_
51-43	8426-8427	,	_
51-44	8428-8431	and	_
51-45	8432-8435	the	_
51-46	8436-8450	reward-control	_
51-47	8451-8461	subnetwork	_
51-48	8462-8471	comprised	_
51-49	8472-8475	the	_
51-50	8476-8481	dlPFC	_
51-51	8482-8483	,	_
51-52	8484-8487	ACC	_
51-53	8488-8496	together	_
51-54	8497-8501	with	_
51-55	8502-8505	OFC	_
51-56	8506-8509	and	_
51-57	8510-8513	INS	_
51-58	8514-8518	that	_
51-59	8519-8525	mainly	_
51-60	8526-8533	exerted	_
51-61	8534-8544	inhibitory	_
51-62	8545-8552	control	_
51-63	8553-8556	for	_
51-64	8557-8566	substance	_
51-65	8567-8573	reward	_
51-66	8574-8575	.	_

52-1	8576-8583	Network	_
52-2	8584-8588	edge	_
52-3	8589-8599	definition	_
52-4	8600-8607	Between	_
52-5	8608-8613	pairs	_
52-6	8614-8616	of	_
52-7	8617-8621	ROIs	_
52-8	8622-8623	,	_
52-9	8624-8634	structural	_
52-10	8635-8646	connections	_
52-11	8647-8651	were	_
52-12	8652-8660	measured	_
52-13	8661-8666	using	_
52-14	8667-8670	the	_
52-15	8671-8684	probabilistic	_
52-16	8685-8690	fiber	_
52-17	8691-8699	tracking	_
52-18	8700-8706	method	_
52-19	8707-8709	in	_
52-20	8710-8713	FSL	_
52-21	8714-8715	.	_

53-1	8716-8720	This	_
53-2	8721-8730	comprised	_
53-3	8731-8733	of	_
53-4	8734-8737	276	_
53-5	8738-8748	structural	_
53-6	8749-8760	connections	_
53-7	8761-8764	for	_
53-8	8765-8769	each	_
53-9	8770-8777	subject	_
53-10	8778-8779	(	_
53-11	8780-8781	a	_
53-12	8782-8793	symmetrical	_
53-13	8794-8796	24	_
53-14	8797-8798	×	_
53-15	8799-8801	24	_
53-16	8802-8808	matrix	_
53-17	8809-8810	)	_
53-18	8811-8812	.	_

54-1	8813-8826	Probabilistic	_
54-2	8827-8832	fiber	_
54-3	8833-8841	tracking	_
54-4	8842-8845	was	_
54-5	8846-8856	repeatedly	_
54-6	8857-8864	sampled	_
54-7	8865-8869	from	_
54-8	8870-8873	the	_
54-9	8874-8887	distributions	_
54-10	8888-8890	of	_
54-11	8891-8901	voxel-wise	_
54-12	8902-8911	principal	_
54-13	8912-8921	diffusion	_
54-14	8922-8932	directions	_
54-15	8933-8935	to	_
54-16	8936-8944	generate	_
54-17	8945-8946	a	_
54-18	8947-8960	probabilistic	_
54-19	8961-8971	streamline	_
54-20	8972-8974	on	_
54-21	8975-8978	the	_
54-22	8979-8987	location	_
54-23	8988-8990	of	_
54-24	8991-8994	the	_
54-25	8995-8999	true	_
54-26	9000-9010	streamline	_
54-27	9011-9014	and	_
54-28	9015-9022	thereby	_
54-29	9023-9028	build	_
54-30	9029-9030	a	_
54-31	9031-9041	connective	_
54-32	9042-9047	value	_
54-33	9048-9051	map	_
54-34	9052-9054	in	_
54-35	9055-9064	diffusion	_
54-36	9065-9070	space	_
54-37	9071-9072	.	_

55-1	9073-9076	All	_
55-2	9077-9080	the	_
55-3	9081-9087	fibers	_
55-4	9088-9092	were	_
55-5	9093-9100	tracked	_
55-6	9101-9105	with	_
55-7	9106-9107	a	_
55-8	9108-9117	curvature	_
55-9	9118-9127	threshold	_
55-10	9128-9130	of	_
55-11	9131-9134	0.2	_
55-12	9135-9136	.	_

56-1	9137-9141	Then	_
56-2	9142-9143	,	_
56-3	9144-9148	both	_
56-4	9149-9152	the	_
56-5	9153-9161	FA-value	_
56-6	9162-9168	images	_
56-7	9169-9172	and	_
56-8	9173-9176	the	_
56-9	9177-9190	probabilistic	_
56-10	9191-9201	streamline	_
56-11	9202-9208	images	_
56-12	9209-9213	were	_
56-13	9214-9220	warped	_
56-14	9221-9225	from	_
56-15	9226-9235	diffusion	_
56-16	9236-9241	space	_
56-17	9242-9246	into	_
56-18	9247-9250	MNI	_
56-19	9251-9256	space	_
56-20	9257-9258	.	_

57-1	9259-9262	The	_
57-2	9263-9273	one-sample	_
57-3	9274-9280	t-test	_
57-4	9281-9284	was	_
57-5	9285-9292	applied	_
57-6	9293-9295	to	_
57-7	9296-9299	the	_
57-8	9300-9310	connective	_
57-9	9311-9316	value	_
57-10	9317-9321	maps	_
57-11	9322-9324	of	_
57-12	9325-9334	addiction	_
57-13	9335-9343	subjects	_
57-14	9344-9346	or	_
57-15	9347-9349	HC	_
57-16	9350-9358	subjects	_
57-17	9359-9360	,	_
57-18	9361-9373	respectively	_
57-19	9374-9375	,	_
57-20	9376-9378	to	_
57-21	9379-9385	define	_
57-22	9386-9396	streamline	_
57-23	9397-9404	regions	_
57-24	9405-9406	.	_

58-1	9407-9410	The	_
58-2	9411-9417	voxels	_
58-3	9418-9422	were	_
58-4	9423-9434	thresholded	_
58-5	9435-9437	at	_
58-6	9438-9439	p	_
58-7	9440-9441	<	_
58-8	9442-9446	0.05	_
58-9	9447-9455	compared	_
58-10	9456-9458	to	_
58-11	9459-9463	zero	_
58-12	9464-9465	.	_

59-1	9466-9469	The	_
59-2	9470-9480	connective	_
59-3	9481-9489	strength	_
59-4	9490-9492	of	_
59-5	9493-9497	each	_
59-6	9498-9502	edge	_
59-7	9503-9506	was	_
59-8	9507-9514	defined	_
59-9	9515-9517	as	_
59-10	9518-9521	the	_
59-11	9522-9529	average	_
59-12	9530-9532	FA	_
59-13	9533-9539	values	_
59-14	9540-9542	of	_
59-15	9543-9546	all	_
59-16	9547-9553	voxels	_
59-17	9554-9558	that	_
59-18	9559-9563	were	_
59-19	9564-9572	included	_
59-20	9573-9575	in	_
59-21	9576-9579	the	_
59-22	9580-9590	streamline	_
59-23	9591-9598	regions	_
59-24	9599-9600	.	_

60-1	9601-9608	Network	_
60-2	9609-9617	analysis	_
60-3	9618-9621	The	_
60-4	9622-9629	average	_
60-5	9630-9640	connective	_
60-6	9641-9649	strength	_
60-7	9650-9652	of	_
60-8	9653-9657	each	_
60-9	9658-9662	edge	_
60-10	9663-9666	was	_
60-11	9667-9675	measured	_
60-12	9676-9679	for	_
60-13	9680-9684	each	_
60-14	9685-9692	subject	_
60-15	9693-9706	independently	_
60-16	9707-9708	,	_
60-17	9709-9718	including	_
60-18	9719-9730	connections	_
60-19	9731-9737	within	_
60-20	9738-9741	the	_
60-21	9742-9756	reward-driving	_
60-22	9757-9767	subnetwork	_
60-23	9768-9769	(	_
60-24	9770-9777	Driving	_
60-25	9778-9779	)	_
60-26	9780-9783	and	_
60-27	9784-9798	reward-control	_
60-28	9799-9809	subnetwork	_
60-29	9810-9811	(	_
60-30	9812-9819	Control	_
60-31	9820-9821	)	_
60-32	9822-9823	,	_
60-33	9824-9835	connections	_
60-34	9836-9843	between	_
60-35	9844-9859	driving/control	_
60-36	9860-9871	subnetworks	_
60-37	9872-9873	(	_
60-38	9874-9889	BTN-connections	_
60-39	9890-9891	)	_
60-40	9892-9893	,	_
60-41	9894-9897	and	_
60-42	9898-9909	connections	_
60-43	9910-9914	with	_
60-44	9915-9926	significant	_
60-45	9927-9938	differences	_
60-46	9939-9946	between	_
60-47	9947-9950	HAs	_
60-48	9951-9954	and	_
60-49	9955-9958	HCs	_
60-50	9959-9960	(	_
60-51	9961-9977	Diff-connections	_
60-52	9978-9979	)	_
60-53	9980-9981	.	_

61-1	9982-9985	DNA	_
61-2	9986-9996	extraction	_
61-3	9997-10000	and	_
61-4	10001-10008	genetic	_
61-5	10009-10018	variation	_
61-6	10019-10028	detection	_
61-7	10029-10036	Genomic	_
61-8	10037-10040	DNA	_
61-9	10041-10044	was	_
61-10	10045-10053	isolated	_
61-11	10054-10058	from	_
61-12	10059-10069	peripheral	_
61-13	10070-10075	blood	_
61-14	10076-10087	lymphocytes	_
61-15	10088-10093	using	_
61-16	10094-10097	the	_
61-17	10098-10104	QIAamp	_
61-18	10105-10108	DNA	_
61-19	10109-10113	Mini	_
61-20	10114-10117	Kit	_
61-21	10118-10119	(	_
61-22	10120-10126	Qiagen	_
61-23	10127-10128	,	_
61-24	10129-10137	Valencia	_
61-25	10138-10139	,	_
61-26	10140-10142	CA	_
61-27	10143-10144	,	_
61-28	10145-10148	USA	_
61-29	10149-10150	)	_
61-30	10151-10152	.	_

62-1	10153-10162	MassArray	_
62-2	10163-10164	(	_
62-3	10165-10173	Sequenom	_
62-4	10174-10175	,	_
62-5	10176-10179	San	_
62-6	10180-10185	Diego	_
62-7	10186-10187	,	_
62-8	10188-10190	CA	_
62-9	10191-10192	,	_
62-10	10193-10196	USA	_
62-11	10197-10198	)	_
62-12	10199-10202	was	_
62-13	10203-10207	used	_
62-14	10208-10210	to	_
62-15	10211-10219	genotype	_
62-16	10220-10223	all	_
62-17	10224-10231	markers	_
62-18	10232-10237	using	_
62-19	10238-10253	allele-specific	_
62-20	10254-10269	Matrix-assisted	_
62-21	10270-10275	laser	_
62-22	10276-10302	desorption/ionization-time	_
62-23	10303-10305	of	_
62-24	10306-10312	flight	_
62-25	10313-10317	mass	_
62-26	10318-10330	spectrometry	_
62-27	10331-10332	.	_

63-1	10333-10340	Primers	_
63-2	10341-10344	and	_
63-3	10345-10354	multiplex	_
63-4	10355-10364	reactions	_
63-5	10365-10369	were	_
63-6	10370-10378	designed	_
63-7	10379-10384	using	_
63-8	10385-10396	RealSNP.com	_
63-9	10397-10404	website	_
63-10	10405-10406	.	_

64-1	10407-10411	None	_
64-2	10412-10414	of	_
64-3	10415-10418	the	_
64-4	10419-10429	individual	_
64-5	10430-10441	proportions	_
64-6	10442-10455	significantly	_
64-7	10456-10464	deviated	_
64-8	10465-10469	from	_
64-9	10470-10484	Hardy–Weinberg	_
64-10	10485-10496	equilibrium	_
64-11	10497-10498	(	_
64-12	10499-10502	HWE	_
64-13	10503-10504	)	_
64-14	10505-10510	among	_
64-15	10511-10514	HCs	_
64-16	10515-10518	and	_
64-17	10519-10522	HAs	_
64-18	10523-10524	.	_

65-1	10525-10528	The	_
65-2	10529-10537	genotype	_
65-3	10538-10542	call	_
65-4	10543-10547	rate	_
65-5	10548-10551	was	_
65-6	10552-10553	>	_
65-7	10554-10556	98	_
65-8	10557-10558	%	_
65-9	10559-10562	for	_
65-10	10563-10567	each	_
65-11	10568-10571	SNP	_
65-12	10572-10573	.	_

66-1	10574-10585	Statistical	_
66-2	10586-10594	analysis	_
66-3	10595-10598	The	_
66-4	10599-10610	statistical	_
66-5	10611-10616	power	_
66-6	10617-10619	of	_
66-7	10620-10626	sample	_
66-8	10627-10631	size	_
66-9	10632-10640	computed	_
66-10	10641-10643	by	_
66-11	10644-10647	the	_
66-12	10648-10654	Quanto	_
66-13	10655-10659	soft	_
66-14	10660-10661	(	_
66-15	10662-10666	http	_
66-16	10667-10668	:	_
66-17	10669-10699	//biostats.usc.edu/Quanto.html	_
66-18	10700-10701	)	_
66-19	10702-10705	was	_
66-20	10706-10712	higher	_
66-21	10713-10717	than	_
66-22	10718-10721	0.9	_
66-23	10722-10723	.	_

67-1	10724-10727	The	_
67-2	10728-10737	variances	_
67-3	10738-10742	were	_
67-4	10743-10750	similar	_
67-5	10751-10758	between	_
67-6	10759-10762	the	_
67-7	10763-10769	groups	_
67-8	10770-10774	that	_
67-9	10775-10779	were	_
67-10	10780-10785	being	_
67-11	10786-10799	statistically	_
67-12	10800-10808	compared	_
67-13	10809-10810	.	_

68-1	10811-10821	Two-sample	_
68-2	10822-10828	t-test	_
68-3	10829-10832	was	_
68-4	10833-10837	used	_
68-5	10838-10840	to	_
68-6	10841-10850	determine	_
68-7	10851-10862	differences	_
68-8	10863-10865	in	_
68-9	10866-10877	demographic	_
68-10	10878-10881	and	_
68-11	10882-10890	clinical	_
68-12	10891-10906	characteristics	_
68-13	10907-10912	using	_
68-14	10913-10917	SPSS	_
68-15	10918-10922	21.0	_
68-16	10923-10931	software	_
68-17	10932-10933	.	_

69-1	10934-10938	Each	_
69-2	10939-10949	structural	_
69-3	10950-10960	connection	_
69-4	10961-10964	was	_
69-5	10965-10973	compared	_
69-6	10974-10981	between	_
69-7	10982-10985	the	_
69-8	10986-10988	HA	_
69-9	10989-10992	and	_
69-10	10993-10995	HC	_
69-11	10996-11002	groups	_
69-12	11003-11008	using	_
69-13	11009-11015	10,000	_
69-14	11016-11030	non-parametric	_
69-15	11031-11042	permutation	_
69-16	11043-11048	tests	_
69-17	11049-11054	based	_
69-18	11055-11057	on	_
69-19	11058-11068	two-sample	_
69-20	11069-11075	t-test	_
69-21	11076-11082	scores	_
69-22	11083-11084	,	_
69-23	11085-11089	with	_
69-24	11090-11091	“	_
69-25	11092-11102	cigarettes	_
69-26	11103-11109	smoked	_
69-27	11110-11113	per	_
69-28	11114-11117	day	_
69-29	11118-11119	”	_
69-30	11120-11123	and	_
69-31	11124-11127	age	_
69-32	11128-11130	as	_
69-33	11131-11141	covariates	_
69-34	11142-11143	.	_

70-1	11144-11147	The	_
70-2	11148-11157	threshold	_
70-3	11158-11160	of	_
70-4	11161-11177	Diff-connections	_
70-5	11178-11181	was	_
70-6	11182-11185	set	_
70-7	11186-11188	at	_
70-8	11189-11190	p	_
70-9	11191-11192	<	_
70-10	11193-11203	0.00018116	_
70-11	11204-11205	(	_
70-12	11206-11214	0.05/276	_
70-13	11215-11216	)	_
70-14	11217-11221	with	_
70-15	11222-11241	multiple-comparison	_
70-16	11242-11252	correction	_
70-17	11253-11255	to	_
70-18	11256-11264	identify	_
70-19	11265-11278	statistically	_
70-20	11279-11290	significant	_
70-21	11291-11302	differences	_
70-22	11303-11304	.	_

71-1	11305-11308	The	_
71-2	11309-11319	assessment	_
71-3	11320-11322	of	_
71-4	11323-11326	HWE	_
71-5	11327-11330	was	_
71-6	11331-11340	performed	_
71-7	11341-11346	using	_
71-8	11347-11350	the	_
71-9	11351-11353	χ2	_
71-10	11354-11369	goodness-of-fit	_
71-11	11370-11374	test	_
71-12	11375-11376	.	_

72-1	11377-11385	Additive	_
72-2	11386-11392	linear	_
72-3	11393-11403	regression	_
72-4	11404-11407	was	_
72-5	11408-11412	used	_
72-6	11413-11416	for	_
72-7	11417-11420	the	_
72-8	11421-11432	association	_
72-9	11433-11441	analysis	_
72-10	11442-11444	of	_
72-11	11445-11449	SNPs	_
72-12	11450-11454	with	_
72-13	11455-11465	structural	_
72-14	11466-11476	connection	_
72-15	11477-11478	,	_
72-16	11479-11483	with	_
72-17	11484-11485	“	_
72-18	11486-11496	cigarettes	_
72-19	11497-11503	smoked	_
72-20	11504-11507	per	_
72-21	11508-11511	day	_
72-22	11512-11513	”	_
72-23	11514-11517	and	_
72-24	11518-11521	age	_
72-25	11522-11524	as	_
72-26	11525-11535	covariates	_
72-27	11536-11541	using	_
72-28	11542-11547	PLINK	_
72-29	11548-11549	.	_

73-1	11550-11557	Linkage	_
73-2	11558-11572	disequilibrium	_
73-3	11573-11574	(	_
73-4	11575-11577	LD	_
73-5	11578-11579	)	_
73-6	11580-11588	analyses	_
73-7	11589-11593	were	_
73-8	11594-11603	performed	_
73-9	11604-11609	using	_
73-10	11610-11619	Haploview	_
73-11	11620-11623	4.1	_
73-12	11624-11625	(	_
73-13	11626-11630	http	_
73-14	11631-11632	:	_
73-15	11633-11667	//www.broad.mit.edu/mpg/haploview/	_
73-16	11668-11669	)	_
73-17	11670-11671	.	_

74-1	11672-11675	The	_
74-2	11676-11685	mediation	_
74-3	11686-11694	analysis	_
74-4	11695-11698	was	_
74-5	11699-11708	performed	_
74-6	11709-11714	using	_
74-7	11715-11718	the	_
74-8	11719-11724	model	_
74-9	11725-11726	4	_
74-10	11727-11729	in	_
74-11	11730-11737	PROCESS	_
74-12	11738-11740	to	_
74-13	11741-11750	bootstrap	_
74-14	11751-11754	the	_
74-15	11755-11763	sampling	_
74-16	11764-11776	distribution	_
74-17	11777-11779	of	_
74-18	11780-11783	the	_
74-19	11784-11792	indirect	_
74-20	11793-11799	effect	_
74-21	11800-11801	.	_

